EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effects of cladribine on intrathecal and peripheral B and plasma cells

Kimberley Allen-Philbey iD, Sophie Stephenson, Gina Doody, Amy MacDougall, Mohammad Aboulwafaali, Francesca Ammoscato, Michael Andrews, Sharmilee Gnanapavan, Gavin Giovannoni, Sofia Grigoriadou iD, Alaco Hickey, David W Holden und 6 weitere

Clinical and Experimental Immunology · 2025

DOI: 10.1093/cei/uxae116 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2025. Verfasst von Kimberley Allen-Philbey und 17 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, UK. Hauptthemen laut MEDLINE: Cladribine, B-Lymphocytes, Plasma Cells, Multiple Sclerosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MS Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Cladribine is a deoxyadenosine analogue that can penetrate the blood–brain barrier. It is used to treat multiple sclerosis (MS). However, the mechanistic understanding of the effect of this highly effective therapy on B cells and plasma cells in the central nervous system compartment is limited. The CLADRIPLAS study examined the effect of cladribine on peripheral and intrathecal B and plasma cell biology in people with MS.

Methods

Thirty-eight people with progressive MS ineligible for- or rejecting-treatment with licenced therapies were recruited and supplied a baseline lumbar puncture. Those exhibiting gadolinium-enhancing or new/enlarging T2 magnetic resonance imaging lesions and/or elevated neurofilament levels were offered subcutaneous cladribine (Litak®). Seven people were eligible; one person died before treatment, and only five completed the first year of treatment. Twenty-two ineligible people were willing to provide a repeat lumbar puncture 12 months later.

Results

The CLADRIPLAS study found no evidence of a difference in the odds of a positive cerebrospinal fluid oligoclonal band result between the cladribine-treated and untreated group. This is probably explained by microarray and in vitro studies, which demonstrated that plasmablasts and notably long-lived plasma cells are relatively resistant to the cytotoxic effect of cladribine compared with memory B cells at physiological concentrations. This was consistent with the loss of intracellular deoxycytidine kinase during antibody-secreting cell differentiation.

Conclusion

CLADRIPLAS indicates that cerebrospinal fluid oligoclonal bands are not rapidly eliminated in most people with MS. This may be explained by the relative lack of direct cytotoxic action of cladribine on long-lived plasma cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CladribineB-LymphocytesPlasma CellsMultiple SclerosisHumansMaleFemaleMiddle AgedAdultOligoclonal BandsMagnetic Resonance ImagingAged

Stichwörter der Autor:innen

B cellscladribinemultiple sclerosisoligoclonal bandsplasma cells

Substanzen

CladribineOligoclonal Bands

Autor:innen und Institutionen

  • Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, UK.
  • Blizard Institute, Centre for Neuroscience, Surgery & Trauma, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.
  • Division of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK.
  • Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK.
  • Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.
  • Department of Immunology, The Royal London Hospital, Barts Health NHS Trust, London, UK.

ORCID-Profile: Kimberley Allen-Philbey, Sofia Grigoriadou, David Baker, Klaus Schmierer

Förderung

  • MS Society

Zitieren

APA

Allen-Philbey, K., Stephenson, S., Doody, G., MacDougall, A., Aboulwafaali, M., Ammoscato, F., Andrews, M., Gnanapavan, S., Giovannoni, G., Grigoriadou, S., Hickey, A., Holden, D. W., Lock, H., Papachatzaki, M., Redha, I., Baker, D., Tooze, R., & Schmierer, K. (2025). Effects of cladribine on intrathecal and peripheral B and plasma cells. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxae116

Vancouver

Allen-Philbey K, Stephenson S, Doody G, MacDougall A, Aboulwafaali M, Ammoscato F, et al. Effects of cladribine on intrathecal and peripheral B and plasma cells. Clinical and Experimental Immunology. 2025. doi:10.1093/cei/uxae116

BibTeX
@article{AllenPhilbey2025,
  author = {Allen-Philbey, Kimberley and Stephenson, Sophie and Doody, Gina and MacDougall, Amy and Aboulwafaali, Mohammad and Ammoscato, Francesca and Andrews, Michael and Gnanapavan, Sharmilee and Giovannoni, Gavin and Grigoriadou, Sofia and Hickey, Alaco and Holden, David W and Lock, Helen and Papachatzaki, Maria and Redha, Iman and Baker, David and Tooze, Reuben and Schmierer, Klaus},
  title = {Effects of cladribine on intrathecal and peripheral B and plasma cells},
  journal = {Clinical and Experimental Immunology},
  year = {2025},
  doi = {10.1093/cei/uxae116}
}
Kostenlos starten →